Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi Syndrome
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of a once daily subcutaneous (SC)
injectable formulation of RM-493 in obese subjects with Prader-Willi syndrome on
tolerability, weight loss and hyperphagia-related behavior. The study drug (RM-493 and
placebo) will be administered in a blinded fashion.
Funding Source - FDA OOPD